论文部分内容阅读
我国的医药产业目前处于一个过渡期,正面临医疗保险制度改革、外资企业竞争、市场趋于饱和等方面的严峻挑战,同时又处于中国加入世界贸易组织的新的历史时期。中美两国就中国加入WTO达成双边协议后,中国长达13年的“复关”和“入世”谈判的艰难历程终于走出困境。WTO进入问题的谈判中,医药产品也是一个敏感问题,很多人担心加入WTO之后,我国的医药行业,特别是国有企业会
China’s pharmaceutical industry is currently in a transitional period and is facing serious challenges in the reform of the medical insurance system, competition of foreign-funded enterprises, and the saturation of the market. At the same time, it is at a new historical period when China joined the World Trade Organization. After China and the United States reached a bilateral agreement on China’s accession to the WTO, the difficult course of China’s 13 years of “re-entry” and “WTO accession” negotiations has finally come out of its predicament. In the negotiation of WTO entry issues, pharmaceutical products are also a sensitive issue. Many people are worried that after joining the WTO, the pharmaceutical industry in China, especially the state-owned enterprises will